Skip to content
Blackberry Empire – Lifestyle
Author:
Boehringer Ingelheim
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
September 23, 2026
Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice
September 17, 2026
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
September 1, 2026
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
August 11, 2026
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
July 16, 2026
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
July 15, 2026
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
June 22, 2026